法国胃癌临床实践指南:诊断、分期、治疗与随访(TNCD多学会联合更新)
法国多学会联合更新胃及胃食管交界腺癌管理指南,基于截至2026年1月的证据将推荐分为A、B、C三级。可切除局部晚期≥cT2和/或cN+推荐围手术期FLOT化疗为标准;转移性疾病一线为铂-氟嘧啶双药,依HER2、claudin18.2、PD-L1及dMMR/MSI状态联合靶向或免疫治疗。
要点
- 可切除局部晚期≥cT2和/或cN+者,围手术期FLOT化疗为标准治疗。
- 转移性一线为铂-氟嘧啶双药,依HER2、claudin18.2、PD-L1、dMMR/MSI加靶向或免疫。
- 生物标志物阴性特定患者可考虑TFOX三药;HER2阳性后线可用T-DXd。
核心结论
- 该法国多学会胃癌指南旨在促进日常临床决策,推荐持续更新,每例应在多学科团队内讨论。
研究设计与样本
- 由法国多个国家医学学会协作制定的胃及胃食管交界腺癌管理指南更新版,推荐基于截至2026年1月发表的科学证据分为A、B、C三级。
主要发现
- 初始分期与风险评估应包括体格检查、内镜及胸腹盆CT扫描。
- 可切除者可用超声内镜行T和N分期,尤其cT3/cT4及低黏附性肿瘤可腹腔镜探查排除隐匿腹膜转移。
- 极早期cT1N0肿瘤单独内镜或手术切除即可。
- 局部晚期≥cT2和/或cN+者围手术期FLOT化疗为标准治疗;近期围手术期FLOT联合度伐利尤单抗并后续度伐利尤单抗维持10个月与生存显著改善相关。
- 转移性一线为铂-氟嘧啶双药,依HER2(曲妥珠单抗)、claudin18.2(佐妥昔单抗)、PD-L1及dMMR/MSI(抗PD1单抗)加靶向和/或免疫;生物标志物阴性特定患者可考虑含多西他赛的TFOX三药。
关键数值与推荐
- 推荐分为A、B、C三级,基于截至2026年1月发表的科学证据水平。
- 围手术期FLOT为局部晚期≥cT2和/或cN+的标准治疗;度伐利尤单抗联合FLOT后维持10个月与生存显著改善相关。
- 转移性一线为铂-氟嘧啶双药;HER2阳性可用曲妥珠单抗,claudin18.2阳性可用佐妥昔单抗,dMMR/MSI可用抗PD1单抗。
- HER2阳性肿瘤后线可用曲妥珠单抗-deruxtecan(T-DXd)。
临床怎么用
- 初诊应完成体格检查、内镜及胸腹盆CT;可切除者按cT/cN选择超声内镜或腹腔镜探查。
- 局部晚期≥cT2和/或cN+优先围手术期FLOT,可评估联合度伐利尤单抗及维持治疗。
- 转移性治疗前检测HER2、claudin18.2、PD-L1及dMMR/MSI以指导联合靶向或免疫。
- 原发灶及转移灶切除不推荐常规进行,仅对系统治疗有效的寡转移高度选择患者个体化考虑。
- 每例患者应在多学科团队内讨论决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The updated edition of the French intergroup guidelines for the management of patients with gastric and gastroesophageal junction adenocarcinoma is a collaborative work of several national medical societies, and available on the website of the French Society of Gastroenterology (SNFGE) (www.tncd.org). METHODS: The recommendations are graded into three categories (A, B, and C), based on the level of scientific evidence published until January 2026. RESULTS: Initial staging and risk assessment should include physical evaluation, endoscopy and computed tomography-scan of the thorax, abdomen, and pelvis. For resectable disease, endoscopic ultrasonography can be used for T and N staging, while laparoscopic exploration may be performed to exclude occult peritoneal metastases, especially for cT3/cT4 and poorly cohesive tumors. Endoscopic or surgical resection alone is appropriate for very early cT1N0 tumors. For locally advanced disease ≥cT2 and/or cN + , the perioperative FLOT chemotherapy is recommended as the standard of care. Recently, the addition of durvalumab to perioperative FLOT followed by durvalumab for 10 months as maintenance therapy was associated with a significant improvement of survival. For metastatic disease, the first-line chemotherapy is based on platinum-fluoropyrimidine combination. The addition of targeted therapy and/or immunotherapy to doublet chemotherapy depends on the tumor biomarker profile, including HER2 (trastuzumab), claudin18.2 (zolbetuximab), PD-L1 and dMMR/MSI phenotype (anti-PD1 monoclonal antibodies). The addition of docetaxel, based on the triplet TFOX regimen may be considered for selected patients with biomarker-negative tumors. Resection of primary tumor and metastases cannot be recommended but may be considered on an individual basis in highly selected patients with oligometastatic disease who respond to systemic treatment. Various drugs are indicated beyond first-line of treatment, including trastuzumab-deruxtecan for HER2-positive tumors. CONCLUSION: These national guidelines on gastric cancer are intended to facilitate decision-making in daily clinical practice. These recommendations are subject to ongoing review. Each individual case should be discussed within a multidisciplinary team.
引用
- Zaanan A, Palle J, Renaud F, et al. Gastric cancer: French intergroup clinical practice guidelines for diagnosis, staging, treatment and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACHBPT, RENAPE, SNFCP). Eur J Cancer. 2026. PMID: 42054784. doi:10.1016/j.ejca.2026.116697
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。